Cancer Chemotherapy and Pharmacology

Article	Citations
EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer	104
A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma	29
Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients	26
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions	24
Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma	23
A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro	23
Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression	23
Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4hydroxycyclophosphamide formation in children with Cancer	23
Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors	23
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study	22
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy	21
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients	20
Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer	19
MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism	18
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations	17
Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma	17
Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway	16
Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration	16
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review	16
Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study	16
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide	16
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells	14
Correction: HER-2 SMASH	14
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms	14
Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study	14

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants	14
Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial	13
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy	13
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer	13
Comment on “Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase”	13
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report	13
Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models	12
An interactive dose optimizer based on population pharmacokinetic study to guide dosing of methotrexate in Chinese patients with osteosarcoma	12
Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical s	12
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)	12
Retraction Note: NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells	12
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study	12
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype	11
Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model	11
Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies	11
Optimized scaling of translational factors in oncology: from xenografts to RECIST	11
Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors	11
Immunoregulatory cyclophilin a improves low-dose chemotherapy with a modulation of the immune tumor microenvironment in experimental models of melanoma B16 and lymphoma EL4 in vivo	11
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma	11
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach	11
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast	10
Real-world pharmacokinetics of trametinib in pediatric low-grade glioma	10
Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia	10
Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing	10
Alternative routes of drug administration: exposure of imatinib using different formulations	10
Hsp90 inhibition sensitizes DLBCL cells to cisplatin	10
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?	10
HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC	10
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors	10
Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways	10
Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management – a comprehensive review	10
Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells	10
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole	9
18β-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis	9
SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer	9
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation	9
Physiologically based pharmacokinetic modeling of ponatinib to describe drug–drug interactions in patients with cancer	9
Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug–drug interactions with oral targeted therapy	9
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure	9
A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis	9
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors	9
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers	9
New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid	9
The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects	9
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma	8
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib	8
Avermectin B1 mediates antitumor activity and induces autophagy in osteosarcoma through the AMPK/ULK1 signaling pathway	8
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing	8
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors	8
NCTR25 fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL	8

Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients	8
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial	8
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs	8
Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions	8
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors	8
Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib	8
Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer	8
Retraction Note: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis	8
Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment	8
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors	7
Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breas	7
Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure	7
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck	7
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer	7
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors	7
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome	7
Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series	7
PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer	7
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma	7
Assay performance and stability of uracil and dihydrouracil in clinical practice	7
Somatic nuclear auto-antigenic sperm protein sensitizes human breast cancer cells to 5-Fluorouracil	7
Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer	7
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies	7
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma	7
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration	7
Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy	7
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies	6
Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia	6
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection	6
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes	6
Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast ca	6
The Gustave Roussy Immune score is a powerful biomarker for predicting therapeutic resistance to chemotherapy in gastric cancer patients	6
Veratricplatin inhibits the progression of hypopharyngeal squamous cell carcinoma FaDu cells in vitro and in vivo	6
Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer	6
Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study	6
Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants	6
Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia	6
Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia	6
Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice	6
Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities	6
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma	6
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer	6
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation	6
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mu	6
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells	6
Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer	6
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point	6
Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations	5
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer	5
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessme	5
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach	5
Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers	5
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer	5
A case report of typhlitis during novel use of ropidoxuridine–capecitabine–radiotherapy for treatment-naïve rectal cancer	5
Roles of DNA polymerase ζ in the radiotherapy sensitivity and oxidative stress of lung cancer cells	5
Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement	5
Berberine chloride suppresses pancreatic adenocarcinoma proliferation and growth by targeting inflammation-related genes: an in silico analysis with in vitro and vivo validation	5
Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to th	5
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma	5
Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors	5
Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-	5
Correction to: Anticancer potential of metformin: focusing on gastrointestinal cancers	5
Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity	5
SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration	5
Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment	5
Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors	5
Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc	5
Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determinati	5
Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-κB signaling and reducing NLRP3 expression in triple-negative breast cancer	5
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine–cisplatin treatment	5
Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer	5
Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies	5
Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review	5
Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors	5
Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients	5
Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study	5
The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer	5
Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment	5
Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management	5
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype	5

The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321	5
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects	5
Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma	5
TMEM120A-mediated regulation of chemotherapy sensitivity in colorectal cancer cells	5
AKR1C4 regulates the sensitivity of colorectal cancer cells to chemotherapy through ferroptosis modulation	4
New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis	4
Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy	4
Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways	4
Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules	4
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations	4
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy	4
The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers	4
Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study	4
Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients	4
Is age just a number? A population pharmacokinetic study of gemcitabine	4
A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells	4
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission	4
Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001)	4
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia	4
Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review	4
Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer	4
Development of a novel nomogram for predicting delayed methotrexate excretion following high-dose methotrexate in adult patients with hematologic malignancies	4
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations	4
Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children’s Oncology Group Study ADVL06B1	4
Comparison of the immunomodulatory potential of platinum-based anti-cancer drugs and anthracyclins on human monocyte-derived cells	4
Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study	4
Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report	4
The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis	4
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study	4
Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma	4
Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells	4
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors	4
Re-thinking the possible interaction between proton pump inhibitors and capecitabine	4
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies	4
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study	4
Anti-drug antibodies in the current management of cancer	3
Retraction Note: Atrial natriuretic peptide protects against cisplatin‑induced granulocytopenia	3
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer	3
Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors	3
A phase I study of the ceramide nanoliposome in patients with advanced solid tumors	3
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy	3
Ferroptosis – a potential feature underlying neratinib-induced colonic epithelial injury	3
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer	3
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast canc	3
Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats	3
Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance	3
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221	3
Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children	3
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo	3
Impact of ALDH1A1 and NQO1 gene polymorphisms on the response and toxicity of chemotherapy in Bangladeshi breast cancer patients	3
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients	3
Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function	3
Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer	3
Model-informed development of a cost-saving dosing regimen for enfortumab vedotin	3
Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study	3
Lurbinectedin-induced thrombocytopenia: the role of body surface area	3
Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma	3
Retraction Note to: Linc‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis	3
Successful desensitization in a patient with metastatic colorectal cancer presenting with regorafenib-mediated fix drug eruption	3
Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responses	3
A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors	3
Pharmacokinetics, mass balance, and metabolism of [14C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjects	2
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial	2
Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells	2
Combination of ionizing radiation and 2-thio-6-azauridine induces cell death in radioresistant triple negative breast cancer cells by downregulating CD151 expression	2
Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice	2
Acute kidney injury in a child treated with cisplatin and amphotericin B	2
An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next	2
Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants	2
A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed	2
WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells	2
Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers	2
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship	2
A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions	2
Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins	2
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis	2
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma	2
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data	2
Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma	2
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach	2
Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling	2
Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma	2
Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy	2
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies	2
Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells	2
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia	2
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer	2
Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis	2
Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2	2
Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers	2
Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials	2
Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML)	2
HER-2 SMASH	2
Clinical implications and chemo-sensitivity of adjuvant chemotherapy in patients with poorly cohesive cells-gastric cancer	2
Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer	2